Not unexpectedly, the pharmaceutical and life sciences sector (PLS) has seen a dramatic decline in merger and acquisition activity in the first half of 2020. Key players normally driving that action are focused on internal resources, instead directing all manpower and funding into COVID-19 research, vaccines and treatments.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,